Description of Medical ServiceThe proposed medical service is an IHC test for evaluation of PD-L1 expression to determine eligibility for treatment with atezolizumab in patients with locally advanced or metastatic TNBC who are previously untreated in the advanced setting. The biopsy sample taken as part of a standard diagnostic process will be used for immunohistochemical testing with PD-L1. The testing would be done by a pathologist alongside other immunohistochemical tests which are done routinely.
Description of Medical ConditionBreast cancer is the most frequently diagnosed cancer among women and is the leading cause of cancer related deaths in women word-wide (1, 2). Triple negative breast cancer, a distinct subtype of breast cancer with the worst prognosis, is characterised immunohistologically by the lack of expression of hormonal estrogen receptor (ER) and progesterone receptor (PgR) and lack of overexpression and/or amplification of the human epidermal growth factor 2 (HER2)/NEU gene (3).
Reason for ApplicationNew MBS item(s)
Medical Service TypeCo-dependent technology
Previous Application NumberNot Applicable
Application FormApplication Form (Word 118 KB)
Application Form (PDF 789 KB)
Consultation SurveyConsultation Survey (Word 70 KB)
Consultation Survey (PDF 394 KB)
PICO ConfirmationPICO Confirmation (Word 469 KB)
PICO Confirmation (PDF 1315 KB)
Public Summary DocumentPublic Summary Document (Word 226 KB)
Public Summary Document (PDF 742 KB)